Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1239-1247

  Derosa, G ^a   Maffioli, P ^b   D'Angelo, A ^a   Salvadeo, S A T ^a   Ferrari, I ^a   Fogari, E ^a   Gravina, A ^a   Mereu, R ^a   Randazzo, S ^a   Cicero, A F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

3 polyunsaturated fatty acids; Combined dyslipidemia; Inflammatory parameters; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; METALLOPROTEINASE; OMEGA 3 FATTY ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; FEMALE; FIBRINOLYSIS; HUMANS; MALE; METALLOPROTEASES; PLACEBOS; PROTEASE INHIBITORS;

EID: 67649675091     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902865601     Document Type: Article

References (54)

1. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958-966
2. Ebbesson SO, Risica PM, Ebbesson LO, et al. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int J Circumpolar Health 2005;64:396-408
3. Skerrett PJ, Hennekens CH. Consumption of fish and fish oils and decreased risk of stroke. Prev Cardiol 2003;1:38-41 (Pubitemid 36278876)
4. Mozaffarian D, Longstreth WT Jr, Lemaitre RN, etal. Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch Intern Med 2005;165:200-206
5. Morris MC, Evans DA, Tangney CC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005;62:1849-1853 (Pubitemid 41785078)
6. Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006;151:857-862
7. Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230
8. Borghi C, Cicero AFG. Blood pressure modulating properties of Omega-3 polyunsaturated fatty acids (PUFA). Another PUFA heart protective effect? High Blood Press Cardiov Prev 2007;14(2):1-7
9. Matsumoto M, Sata M, Fukuda D, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008;197(2):524-533
10. Delbosc S, Glorian M, Le Port AS, et al. The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol 2008;172(5):1430-1440 (Pubitemid 351671555)
11. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361(9356):477-485 (Pubitemid 36173713)
12. International Lipid Information Bureau. Third edition. The ILIB lipid handbook for clinical practice: Dyslipidemia and coronary heart disease. New York,2003. p. 1-242
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
14. European Diabetes Policy Group. A desktop guide to type2 diabetes mellitus. Diab Med 1999;16:716-730 (Pubitemid 29459269)
15. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-266
16. Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II).J Clin Chem Clin Biochem 1978;15:121-130
17. Wahlefeld AW. Second English edititon. Methods of enzymatic analysis: Triglycerides determination after enzymatic hydrolysis, Academic Press, Inc., New York, 1974. p. 18-31
18. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
20. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-438
21. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1959;17:237-246
22. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. J Chromatography 1987;422:43-52 (Pubitemid 17167357)
23. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45(12):2136-2141
24. Scanu AM, Scandian L. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med 1991;36:249-270
25. Uterman G, Weber W. Protein composition of lipoprotein (a). J Clin Invest 1987;80:458-465
26. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
27. Fujimoto N, Mouri N, Iwata K, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993;221(1-2):91-103
28. Fujimoto N, Hosokawa N, Iwata K, et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994;231(1):79-88
29. Clark IM, Powell LK, Wright JK, Cawston TE. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991;11(2):76-85
30. Fujimoto N, Zhang J, Iwata K, et al. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta 1993;220(1):31-45
31. Winer BJ. Statistical principles in experimental design, Second edition. McGraw-Hill New York, 1971
32. Sierevogel MJ, Pasterkamp G, de Kleijn DP, Strauss BH. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003;9(13):1033-1040 (Pubitemid 36443205)
33. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003;26(2):55-59 (Pubitemid 36182635)
34. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma level of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217
35. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868
36. Derosa G, Cicero AF, Scalise F, et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007;14(1):45-51
37. Derosa G, D'Angelo A, Scalise F, et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22(6):361-370
38. Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006;13(3):227-231
39. Derosa G, Avanzini MA, Geroldi D, et al. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;70(2):119-125
40. Derosa G, D'Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007;33(2):129-134
41. Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15(4):219-224
42. Cicero AF, Derosa G, Manca M, et al. Vascular remodelling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007;14(4-5):193-198
43. Derosa G, Cicero AFG, D'Angelo A, et al. Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy. High Blood Press Cardiov Prev 2006;13(2):47-52
44. Lee JH, O'keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83(3):324-332
45. Furenes EB, Seljeflot I, Solheim S, et al. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand J Clin Lab Invest 2008;68(3):177-184
46. Aarsetøy H, Brügger-Andersen T, Hetland Ø, et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006;95(2):329-336
47. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-2049
48. Cheng M, Hashmi S, Mao X, Zeng QT. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008;24(5):385-390 (Pubitemid 351877358)
49. Neschen S, Morino K, Dong J, et al. n-3 Fatty Acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-α- dependent manner. Diabetes 2007;56:1034-1041 (Pubitemid 46525082)
50. Winzell MS, Pacini G, Ahre'n B. Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. Am J Physiol Endocrinol Metab 2006;290:347-354
51. Morvarid K, Skurnik G, Naour N, et al. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007;86:1670-1679 (Pubitemid 350232182)
52. Neschen S, Morino K, Rossbacher JC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006;55:924-928
53. Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006;49:394-397
54. Rodríguez-Cruz M, Tovar AR, del Prado M, Torres N. Molecular mechanisms of action and health benefits of polyunsaturated fatty acids. Rev Invest Clin 2005;57(3):457-472 (Pubitemid 41223257)